TIGERMED to Seek Shareholder Approval for A-Share Repurchase at 9 June 2026 EGM

Bulletin Express
05/19

Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has issued a proxy form outlining matters to be decided at its Second Extraordinary General Meeting (EGM) scheduled for 3:00 p.m. on 9 June 2026 at the company’s Hangzhou headquarters.

The sole agenda item is a special resolution authorising the repurchase of A-shares via centralized price bidding. Key elements up for approval include:

• Purpose and intended use of the repurchased shares.

• Confirmation that statutory and regulatory conditions for the buyback are met.

• Repurchase method, share class, quantity, and proportion relative to total share capital.

• Total capital allocation, funding source, and pricing framework or range.

• Duration of the repurchase period.

• A mandate empowering the Board to handle all procedural matters related to the buyback.

Shareholders may appoint the EGM chairman or another proxy to vote. Completed proxy forms, together with any power of attorney, must reach the H-share registrar (Tricor Investor Services Limited, Hong Kong) at least 24 hours before the meeting. Attendance requires presentation of identity documents.

Completion and return of the proxy form do not preclude shareholders from attending and voting in person. All times reference Hong Kong local time.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10